Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 6;13(7):e0198877.
doi: 10.1371/journal.pone.0198877. eCollection 2018.

Is it time to consider the expression of specific-pituitary hormone genes when typifying pituitary tumours?

Araceli García-Martínez  1 , Johana Sottile  1 , Carmen Fajardo  2 , Pedro Riesgo  3 , Rosa Cámara  4 , Juan Antonio Simal  5 , Cristina Lamas  6 , Hernán Sandoval  7 , Ignacio Aranda  8 , Antonio Picó  9
Affiliations

Is it time to consider the expression of specific-pituitary hormone genes when typifying pituitary tumours?

Araceli García-Martínez et al. PLoS One. .

Abstract

The aim of the present study is to check whether we can replicate, in an independent series, previous results showing that the molecular study of pituitary-specific gene expression complements the inmunohistochemical identification of pituitary neuroendocrine tumours. We selected 112 patients (51 (46.4%) women; mean age 51.4±16 years; 102 macroadenomas (91.9%), 9 microadenomas (8.1%)) with complete clinical, radiological, immunohistochemical and molecular data from our data set of pituitary neuroendocrine tumours. Patients were different from those previously studied. We measured the expression of the pituitary-specific hormone genes and type 1 corticotrophin-releasing hormone and arginine vasopressin 1b receptors, by quantitative real-time polymerase chain reaction using TaqMan probes. Afterwards, we identified the different pituitary neuroendocrine tumour subtypes following the 2017 World Health Organization classification of pituitary tumours, calculating the concordance between their molecular and immuhistochemical identification. The concordance between molecular and immunohistochemical identification of functioning pituitary neuroendocrine tumours with the clinical diagnosis was globally similar to the previous series, where the SYBR Green technique was used instead of TaqMan probes. Our results also corroborated the poor correlation between molecular and immunohistochemical detection of the silent pituitary neuroendocrine tumour variants. This discrepancy was more remarkable in lactotroph, null-cell and plurihormonal pituitary neuroendocrine tumours. In conclusion, this study validates the results previously published by our group, highlighting a complementary role for the molecular study of the pituitary-specific hormone genes in the typification of pituitary neuroendocrine tumours subtypes.

PubMed Disclaimer

Conflict of interest statement

This work is funded by Novartis Oncology through the Spanish Society of Endocrinology and Nutrition (SEEN). This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Linear regression between PRL gene expression in seven functioning lactotropinomas and the dose of cabergoline administered prior to surgery.
See this image and copyright information in PMC

References

    1. Lopes MBS. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 2017;134: 521–535. doi: 10.1007/s00401-017-1769-8 - DOI - PubMed
    1. Asa SL, Casar-Borota O, Chanson P, Delgrange E, Earls P, Ezzat S, et al. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer. 2017;24: C5–C8. doi: 10.1530/ERC-17-0004 - DOI - PubMed
    1. Nishioka H, Inoshita N, Mete O, Asa SL, Hayashi K, Takeshita A, et al. The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas. Endocr Pathol. 2015;26: 349–55. doi: 10.1007/s12022-015-9398-z - DOI - PubMed
    1. Tani Y, Sugiyama T, Izumiyama H, Yoshimoto T, Yamada S, Hirata Y. Differential gene expression profiles of POMC-related enzymes, transcription factors and receptors between non-pituitary and pituitary ACTH-secreting tumors. Endocr J. 2011;58: 297–303. doi: 10.1507/endocrj.K10E-389 - DOI - PubMed
    1. Raverot G, Wierinckx A, Jouanneau E, Auger C, Borson-Chazot F, Lachuer J, et al. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing’s disease. Eur J Endocrinol. European Society of Endocrinology; 2010;163: 35–43. doi: 10.1530/EJE-10-0076 - DOI - PubMed

Publication types

Substances